KLP Kapitalforvaltning AS Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA)

KLP Kapitalforvaltning AS acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 19,600 shares of the company’s stock, valued at approximately $99,000.

Other hedge funds have also made changes to their positions in the company. Vontobel Holding Ltd. bought a new stake in shares of Humacyte in the 4th quarter worth approximately $50,000. Brookstone Capital Management bought a new position in Humacyte in the fourth quarter worth $56,000. ACT Wealth Management LLC acquired a new stake in Humacyte during the fourth quarter worth $57,000. HighTower Advisors LLC bought a new stake in Humacyte in the 4th quarter valued at $66,000. Finally, Atria Wealth Solutions Inc. acquired a new position in shares of Humacyte in the 4th quarter valued at $130,000. Institutional investors own 44.71% of the company’s stock.

Insider Transactions at Humacyte

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. This represents a 121.34 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Wednesday, March 26th. Benchmark restated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Trading Up 2.6 %

Shares of Humacyte stock opened at $1.57 on Friday. The stock has a market capitalization of $227.40 million, a price-to-earnings ratio of -1.17 and a beta of 1.62. The firm’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $4.20. Humacyte, Inc. has a 1-year low of $1.15 and a 1-year high of $9.97.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. As a group, equities research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.